Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off
Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term outlook is unlikely to change
In this series, The Business Times delves into the state of Singapore’s biotech scene, exploring a key challenge: converting its world-class research and development output into commercial victories.
While our first story looked at the reasons behind why few home-grown companies are listing on the Singapore Exchange, this instalment looks upstream and finds a more vibrant picture as international biotech venture capital firms head to Singapore. Upcoming stories will explore the macroeconomic headwinds facing the sector and the future direction of the industry.
[SINGAPORE] International biotech venture capital (VC) firms are flocking to Singapore, drawn by the Asia-Pacific region’s growing life sciences sector, with one more European VC confirmed to set up operations before year-end.
TRENDING NOW
From legacy to launch: Francis Yeoh and Yeoh Pei Xien on family unity and YTL’s next‑gen ventures
Things to know about DBS’ incoming chairman Anthony Lim
Wealthy Indonesians snap up government bonds as yields near 8%: OCBC
From local AI partnerships to global opportunities: How MNCs help Singapore firms scale
